June 16, 2015
June 13, 2015
The New York Times
WASHINGTON, D.C. — June 3, 2015 — The Sabin Vaccine Institute Product Development Partnership (Sabin PDP) today released an update on a Phase 1 clinical trial of its vaccine candidate to prevent intestinal schistosomiasis, Sm-TSP-2/Alhydrogel®. Schistosomiasis is one of the most pervasive neglected tropical diseases (NTDs) affecting the world’s poorest communities. The Sabin PDP is based at the Sabin Vaccine Institute and Texas Children’s Hospital Center for Vaccine Development at Baylor College of Medicine (BCM) in Houston, Texas.
April 25, 2015
May 11, 2015
April 23, 2015
U.S. Department of State: Bureau of Public Affairs
WASHINGTON, D.C. — April 15, 2015 — The Sabin Vaccine Institute (Sabin) presented the 2015 Albert B. Sabin Gold Medal Award to Roger I. Glass, MD, PhD, director of the Fogarty International Center and associate director for international research at the National Institutes of Health. Dr. Glass was recognized for his many contributions to improving children’s health worldwide, including novel scientific research for the prevention of gastroenteritis from rotaviruses and noroviruses.